30
Participants
Start Date
November 8, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
BET Bromodomain Inhibitor ZEN-3694
Given PO
Biopsy Procedure
Undergo biopsy
Biospecimen Collection
Undergo collection of blood samples
Capecitabine
Given PO
Computed Tomography
Undergo CT and PET/CT
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET/CT
SUSPENDED
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
RECRUITING
Montefiore Medical Center-Einstein Campus, The Bronx
RECRUITING
Montefiore Medical Center-Weiler Hospital, The Bronx
RECRUITING
Montefiore Medical Center - Moses Campus, The Bronx
RECRUITING
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
RECRUITING
University of Florida Health Science Center - Gainesville, Gainesville
RECRUITING
Vanderbilt Breast Center at One Hundred Oaks, Nashville
RECRUITING
Vanderbilt University/Ingram Cancer Center, Nashville
RECRUITING
University of Cincinnati Cancer Center-West Chester, West Chester
RECRUITING
University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
RECRUITING
Memorial Hospital East, Shiloh
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
Siteman Cancer Center-South County, St Louis
RECRUITING
Siteman Cancer Center at Christian Hospital, St Louis
RECRUITING
Siteman Cancer Center at West County Hospital, Creve Coeur
RECRUITING
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
RECRUITING
University of Kansas Cancer Center, Kansas City
RECRUITING
University of Kansas Clinical Research Center, Fairway
RECRUITING
University of Kansas Hospital-Westwood Cancer Center, Westwood
RECRUITING
University of Oklahoma Health Sciences Center, Oklahoma City
RECRUITING
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
RECRUITING
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
National Cancer Institute (NCI)
NIH